

EPI Update for Friday, November 20, 2015
Center for Acute Disease Epidemiology (CADE)
Iowa Department of Public Health (IDPH)

Items for this week's EPI Update include:

- **Mumps update**
- **Influenza update**
- **Meningococcal vaccine information**
- **Iowa Acute Disease Monthly Update**
- **Meeting announcements and training opportunities**

Mumps update

Since July 12th, 165 laboratory confirmed cases of mumps have been reported; 139 cases in Johnson County and 26 in the rest of the state. For mumps statistics, visit idph.iowa.gov/ehi/mumps/status-updates.

Public Health and the University of Iowa are recommending a third dose of MMR vaccine for all University of Iowa students under the age of 25. For more information on mumps, visit idph.iowa.gov/ehi/mumps.

Influenza update

Two subtypes of the influenza A virus have been detected by the Iowa Influenza Surveillance Network as circulating in Iowa- A(H3) and A(H1N1) with the H3 sub-type predominating. Current laboratory data suggests that the 2015-2016 influenza vaccine is well matched against circulating viruses. CDC and IDPH recommend an annual influenza vaccination for everyone 6 months of age and older. As of November 14th, over 578,000 doses of influenza vaccine in Iowa had been administered and reported to the Iowa Immunization Registry Information System (IRIS).

For information about influenza surveillance in Iowa, visit idph.iowa.gov/influenza/reports.

Meningococcal vaccine information

The quadrivalent meningococcal conjugate vaccines (Menactra or Menveo) protect against meningitis serogroups A, C, Y, and W-135. The CDC recommends a single dose for all adolescents at ages 11-12 years with a booster between ages 16-18 years.

The newest two meningococcal vaccines protect against most strains of serogroup B meningitis. They are routinely recommended for high-risk patients age 10 years and older who have asplenia (functional or anatomic) or complement component deficiencies, are part of a Meningitis B outbreak, or are microbiologists routinely exposed to isolates of *Neisseria meningitidis*.

On October 23, 2015 the CDC published a category B recommendation allowing providers to administer meningococcal B vaccine to their patients to provide short-term

protection against most strains of serogroup B meningitis. A category B recommendation means the meningitis B vaccines are permissively recommended based on their providers' discretion. This permissive recommendation is to protect those not specifically at high risk; the recommended age for low-risk individuals is 16-23 year olds, with a preference to be given between ages 16-18 years.

There are two brands of meningitis B vaccine available. The two brands should *not* be used interchangeably. Trumenba (Wyeth Pharmaceuticals, Inc.) is a three-dose series to be given at 0, 2 month, 6 month intervals. Bexsero (Novartis Vaccines) is a two-dose series to be given at 0 and 1 month intervals.

To view the most current meningococcal recommendations from the CDC, visit www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm.

To view full recommendations for meningococcal B vaccinations, visit www.cdc.gov/mmwr/preview/mmwrhtml/mm6441a3.htm.

Iowa Acute Disease Monthly Update

The new issue of the Iowa Acute Disease Monthly Update is available on our website. Visit <http://idph.iowa.gov/CADE> and scroll down to 'Reports' or access the report directly at idph.iowa.gov/Portals/1/userfiles/79/Reports/Misc/IADMU%20Oct%2015.pdf.

Meeting announcements and training opportunities

None

Have a healthy and happy week!

Center for Acute Disease Epidemiology
Iowa Department of Public Health
800-362-2736